| Identification | Back Directory | [Name]
jolkinolide A | [CAS]
37905-07-0 | [Synonyms]
jolkinolide A
(5β,9β,10α)-8β,14β:12,16-Diepoxyabieta-11,13(15)-dien-16-one
(4aR,6aS,7aβ)-2,3,4,4aα,5,6,11aα,11b-Octahydro-4,4,8,11bβ-tetramethyl-1H-oxireno[1,10a]phenanthro[3,2-b]furan-9(7aH)-one
1H-Oxireno[1,10a]phenanthro[3,2-b]furan-9(7aH)-one, 2,3,4,4a,5,6,11a,11b-octahydro-4,4,8,11b-tetramethyl-, (4aR,6aS,7aR,11aS,11bR)- | [Molecular Formula]
C20H26O3 | [MOL File]
37905-07-0.mol | [Molecular Weight]
314.42 |
| Hazard Information | Back Directory | [Uses]
Jolkinolide A can be used as a bone marrow mesenchymal stem cell osteogenic differentiation accelerator. It can be developed using matrix solid-phase dispersion coupled with high-performance liquid chromatography. | [Definition]
ChEBI: A natural product found in Euphorbia fischeriana. | [in vivo]
Jolkinolide A (40 mg/kg; i.p.; once every 3 days, for 2 months) inhibits the expression of the VEGF protein in A549 cell xenograft tumor model in mouse[1]. | Animal Model: | Female BALB/c nude mice (4-5 weeks old) injected with A549 cells[1] | | Dosage: | 40 mg/kg | | Administration: | Intraperitoneal injection; once every 3 days for 2 months | | Result: | Significantly inhibited the expression of VEGF protein on the first, 10th, 30th, 45th, and 60th day of administration. |
|
|
| Company Name: |
BioBioPha Co., Ltd.
|
| Tel: |
0871-65217109 13211707573; |
| Website: |
http://www.biobiopha.com |
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|